Preliminary laboratory tests have indicated that Sotrovimab performs best against the Omicron variant. This may be due to the fact that Sotrovimab was designed to target a part of the spike protein that did not mutate between previous coronavirus strains and the Omicron variant.
Read More »Last night, the FDA authorized a COVID-19 monoclonal antibody treatment by AstraZeneca for immunocompromised individuals, who did not produce sufficient antibodies following vaccination.
Read More »New research suggests how COVID-19 adenovirus vaccines may lead to extremely rare cases of thrombosis with thrombocytopenia syndrome (TTS), an autoimmune response which can lead to fatal blood clots. Thrombosis with thrombocytopenia was verified by the WHO as a possible adverse event to AstraZeneca and Johnson & Johnson COVID-19 vaccines earlier this year, following the first but rarely after the second dose.
Read More »A comment piece published in The Lancet Rheumatology examined the results of a questionnaire assessing adverse events in those with autoimmune disease (AD) following their first COVID-19 vaccination. Participants were asked (but not obligated) to recruit a “healthy” control of similar age and sex. They were asked whether they had 1) received a COVID-19 vaccine 2) if so, whether they experienced any local or systemic adverse events in the 7 days following vaccination 3) if so, to report the severity and duration of such adverse events. Patients were also asked to monitor any changes in their autoimmune disease for up to two months post-vaccination.
Read More »